Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

mRNA Loaded Dendritic Cell (DC) Development Service: Multi-Epitope Delivery for Robust Immunotherapy

Q: How does this service compare to direct in vivo mRNA vaccine delivery?

While direct in vivo mRNA delivery has shown great promise, our ex vivo DC engineering approach offers distinct advantages. It provides precise control over the antigen payload and DC activation status, potentially reducing systemic toxicities and overcoming immune suppression often found in the tumor microenvironment.

Online Inquiry

Background Service What We Can Offer Workflow Highlights Published Data FAQs Contact

Creative Biolabs provides an mRNA-loaded dendritic cell (DC) development service that utilizes advanced ex vivo mRNA engineering techniques and multi-epitope antigen presentation platforms to accelerate therapeutic development, enhance targeted anti-tumor responses, and support the generation of effective cancer immunotherapies against heterogeneous tumors.

Introduction

Dendritic cells (DCs) are master regulators of the immune system, uniquely capable of initiating and amplifying anti-tumor T cell responses. Modern immunotherapy capitalizes on its role to overcome tumor-induced immune suppression. The advent of mRNA technology offers unprecedented precision in programming DCs with multiple tumor antigens and immunomodulatory signals. This approach bypasses limitations of direct in vivo delivery and leverages DCs' inherent ability to present antigens and activate T cells effectively.

Service

Creative Biolabs delivers a comprehensive solution for advancing cancer immunotherapy. Our service provides precisely engineered dendritic cells, optimized through ex vivo mRNA loading, to tackle tumor heterogeneity and immune evasion. We enable the generation of potent, multi-faceted anti-tumor immune responses, including robust CD8⁺ cytotoxic T lymphocyte (CTL) activity and broad epitope recognition. Clients can expect custom-designed mRNA constructs encoding multiple tumor antigens and co-stimulatory molecules, ensuring tailored and highly effective cellular vaccines. Our rigorous functional validation guarantees the therapeutic relevance of the engineered DCs.

Multi-Epitope mRNA Design: Custom design of synthetic mRNA encoding multiple tumor-associated or neoantigen epitopes, ensuring broad and personalized immune activation.
Efficient mRNA Loading into DCs: High-efficiency delivery of designed mRNA into dendritic cells using optimized methods—such as electroporation or lipid nanoparticle systems—to maximize antigen expression while preserving DC viability.
Functional Validation & Immune Activation Assessment: Post-transfection validation involving phenotypic characterization, antigen presentation studies, and T-cell activation assays to confirm robust immunogenic functionality of the mRNA-loaded DCs.

What We Can Offer

Custom mRNA Design & Synthesis

Advanced design with codon optimization, nucleoside mods, and capping for stability/efficiency; supports multi-epitope tumor/neoantigen constructs.

Ex Vivo DC Engineering

High-efficiency mRNA loading, including co-stimulatory molecules for DC maturation.

Antigen Presentation Platforms

MHC I/II-targeted mRNA constructs to stimulate CD8⁺/CD4⁺ T cells for anti-tumor responses.

Functional Validation

In vitro/in vivo assays for DC maturation, T-cell activation, and anti-tumor efficacy in animal models.

Formulation Expertise

mRNA stability/encapsulation strategies (e.g., LNP principles) to ensure pre-transfection integrity.

Service Process

The workflow of the mRNA-loaded DC development service. (Creative Biolabs Original)

Key Advantages

Stability & Quality Assurance: Leveraging nucleic acid/cellular therapy expertise, we implement quality systems for mRNA stability in DCs, ensuring consistent performance for research-grade materials.
Collaborative Customization: Seasoned biology teams tailor services to project goals—from antigen selection/mRNA mods to DC source/functional assays—aligning with unique research objectives.
Stability Expertise: Foundational mRNA formulation knowledge ensures stability and cold-chain compatibility, enhancing construct robustness for DC loading.

Supporting data

Summary: This study designed mRNA lipid nanoparticle vaccines targeting highly conserved HIV protease cleavage sites to enhance cellular immunity, with a cold-chain compatible formula. Mouse trials showed it triggered specific CD8 memory T cells systemically and at mucosal sites, with little CD4 T cell activation, confirming its potential as an effective HIV preventive vaccine.

Fig.1 Exploring the in vivo efficacy of mRNA vaccines. (OA Literature) Fig.1 Investigations into the in vivo efficacy of mRNA vaccines.¹

FAQs

Q1: How does this service compare to direct in vivo mRNA vaccine delivery?

A1: While direct in vivo mRNA delivery has shown great promise, our ex vivo DC engineering approach offers distinct advantages. It provides precise control over the antigen payload and DC activation status, potentially reducing systemic toxicities and overcoming immune suppression often found in the tumor microenvironment.

Q2: What kind of support can I expect after the deliverables are provided?

A2: Creative Biolabs is committed to your success. Our support extends beyond final delivery, offering scientific consultation to assist with data interpretation, integration into your downstream studies, and troubleshooting. We aim to be a long-term partner in your immunotherapy development journey.

Q3: Can your engineered DCs be used in combination with other immunotherapies?

A3: Absolutely. Our mRNA-loaded DCs are designed to prime robust T-cell responses, making them ideal candidates for combination therapies, such as with immune checkpoint inhibitors. By enhancing the initial immune recognition, they can synergize with other modalities to achieve superior therapeutic outcomes. We encourage discussion on potential combination strategies.

Why Choose Us

At Creative Biolabs, our mRNA-loaded DC development service represents a fusion of cutting-edge mRNA technology and advanced cellular engineering. We empower researchers and pharmaceutical companies to overcome the complexities of cancer immunology, delivering precisely tailored, multi-epitope engineered dendritic cells designed to elicit robust and lasting anti-tumor immunity.

Customer Reviews

"The ability to precisely deliver multiple epitopes via engineered DCs has facilitated our studies on overcoming tumor immune escape. Creative Biolabs' expertise in designing the mRNA constructs and their efficient electroporation technique is unparalleled, saving us considerable development time." – Pr. Sh Ka.

"Creative Biolabs provided a highly reproducible and efficient service for generating our customized mRNA-DCs. Their attention to detail in quality control and the clarity of their deliverables allowed us to confidently integrate these cells into our therapeutic vaccine strategy. The consistent performance exceeded our expectations." – Ms. Aa Lu.

How to Contact Us

Feel free to reach out at any time to obtain detailed insights into our mRNA-loaded DC development service. Our expertise spans custom mRNA design, ex vivo DC engineering, and functional validation. Let's discuss how our tailored solutions can align with your project goals and advance your research in tumor immunotherapy.

Reference

Mandal, Subhra et al. "A long-term stable cold-chain-friendly HIV mRNA vaccine encoding multi-epitope viral protease cleavage site immunogens inducing immunogen-specific protective T cell immunity." Emerging microbes & infections vol. 13,1 (2024): 2377606. https://doi.org/10.1080/22221751.2024.2377606. Distributed under Open Access License CC BY 4.0, without modification.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.